{"filing":{"accession_number":"0001493152-26-033593","cik":"0001505497","ticker":"BRTX","company_name":"BioRestorative Therapies, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505497/000149315226033593/form8-k.htm"},"events":[{"id":18519,"run_id":16647,"accession_number":"0001493152-26-033593","anchor_item_number":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the departure of Lance Alstodt (President, CEO, and Chairman) and Robert Kristal (CFO) on July 13, 2026, both asserting \"Good Reason\" resignations tied to a claimed Change in Control. While the Board disputes the validity of these claims and has reserved all rights, the departures of the CEO and CFO are material events that would affect a reasonable investor's assessment of the registrant. The filing also includes amendments to executive employment agreements narrowing Change in Control triggers and the appointment of interim leadership, but the principal disclosed action centers on the departure of two key executives.","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":17350,"accession_number":"0001493152-26-033593","item_number":null,"item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the departure of Lance Alstodt (President, CEO, and Chairman) and Robert Kristal (CFO) on July 13, 2026, both asserting \"Good Reason\" resignations tied to a claimed Change in Control. While the Board disputes the validity of these claims and has reserved all rights, the departures of the CEO and CFO are material events that would affect a reasonable investor's assessment of the registrant. The filing also includes amendments to executive employment agreements narrowing Change in Control triggers and the appointment of interim leadership, but the principal disclosed action centers on the departure of two key executives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T21:31:36.867974+00:00","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-07-16"}]}